NCT01700036View on ClinicalTrials.gov

A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

July 31, 2013

Primary Completion Date

October 31, 2016

Study Completion Date

October 26, 2018

Conditions
Graft vs Host Disease
Interventions
DRUG

Alpha-1-Antitrypsin (AAT)

AAT (Zemaira) will be administered at a dose of 60mg/kg (actual weight) on D1, 4, 8, 12, 16, 20, 24, and 28. A second course of treatment will not be given.

Trial Locations (2)

48109

University of Michigan Cancer Center, Ann Arbor

02215

Dana-Farber Cancer Institute, Boston

Sponsors

Collaborators (1)

CSL Behring
All Listed Sponsors
collaborator

CSL Behring

INDUSTRY

collaborator

The Leukemia and Lymphoma Society

OTHER

lead

University of Michigan Rogel Cancer Center

OTHER